These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25885010)

  • 1. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
    Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
    Farmer CA; Brown NV; Gadow KD; Arnold LE; Kolko DG; Findling RL; Molina BS; Buchan-Page KA; Rice RR; Bangalore SS; Bukstein O; Rundberg-Rivera EV; McNamara N; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):213-24. PubMed ID: 25885011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
    Rundberg-Rivera EV; Townsend LD; Schneider J; Farmer CA; Molina BB; Findling RL; Gadow KD; Bukstein OG; Arnold LE; Kolko DJ; Buchan-Page KA; McNamara NK; Michel C; Austin A; Kipp H; Rice RR; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):225-33. PubMed ID: 25885012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.
    Findling RL; Townsend L; Brown NV; Arnold LE; Gadow KD; Kolko DJ; McNamara NK; Gary DS; Kaplin DB; Farmer CA; Kipp H; Williams C; Butter EM; Bukstein OG; Rice R; Buchan-Page K; Molina BS; Aman MG
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):52-65. PubMed ID: 28212067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
    Aman MG; Bukstein OG; Gadow KD; Arnold LE; Molina BS; McNamara NK; Rundberg-Rivera EV; Li X; Kipp H; Schneider J; Butter EM; Baker J; Sprafkin J; Rice RR; Bangalore SS; Farmer CA; Austin AB; Buchan-Page KA; Brown NV; Hurt EA; Grondhuis SN; Findling RL
    J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):47-60.e1. PubMed ID: 24342385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
    Gadow KD; Arnold LE; Molina BS; Findling RL; Bukstein OG; Brown NV; McNamara NK; Rundberg-Rivera EV; Li X; Kipp HL; Schneider J; Farmer CA; Baker JL; Sprafkin J; Rice RR; Bangalore SS; Butter EM; Buchan-Page KA; Hurt EA; Austin AB; Grondhuis SN; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):948-959.e1. PubMed ID: 25151418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
    Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.
    Gadow KD; Brown NV; Arnold LE; Buchan-Page KA; Bukstein OG; Butter E; Farmer CA; Findling RL; Kolko DJ; Molina BS; Rice RR; Schneider J; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):469-78. PubMed ID: 27238065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings.
    Barterian JA; Arnold LE; Brown NV; Farmer CA; Williams C; Findling RL; Kolko DJ; Bukstein OG; Molina BSG; Townsend L; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2017 Dec; 56(12):1026-1033. PubMed ID: 29173736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
    Farmer CA; Epstein JN; Findling RL; Gadow KD; Arnold LE; Kipp H; Kolko DJ; Butter E; Schneider J; Bukstein OG; McNamara NK; Molina BS; Aman MG
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):117-124. PubMed ID: 27348211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
    Günther T; Herpertz-Dahlmann B; Jolles J; Konrad K
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):725-35. PubMed ID: 17201616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardized Observation Analogue Procedure in the Treatment of Severe Childhood Aggression Study.
    Grondhuis SN; Farmer CA; Arnold LE; Gadow KD; Findling RL; Molina BSG; Kolko DJ; Buchan-Page KA; Rice RR; Butter EM; Aman MG
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):48-54. PubMed ID: 31730370
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B; Lopes V; Lehman R
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
    Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
    J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
    Turgay A; Binder C; Snyder R; Fisman S
    Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
    Snyder R; Turgay A; Aman M; Binder C; Fisman S; Carroll A;
    J Am Acad Child Adolesc Psychiatry; 2002 Sep; 41(9):1026-36. PubMed ID: 12218423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
    Armenteros JL; Lewis JE; Davalos M
    J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):558-565. PubMed ID: 17450046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.